Related Experiment Video

Updated: Jul 18, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Expression of CYP2E1 in human nasopharynx and its metabolic effect in vitro

De-Fu Hou1, Shui-Liang Wang, Zhi-Min He

  • 1Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, 410078, P.R. China.

Molecular and Cellular Biochemistry
|December 6, 2006
PubMed

Insights

Cytochrome P450 2E1 (CYP2E1) is expressed in nasopharyngeal carcinoma (NPC) and may activate nitrosamines, contributing to cancer. A new cell line allows studying CYP2E1

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Nitrosamines are carcinogens that require bioactivation by Cytochrome P450 2E1 (CYP2E1) to exert their effects.
  • Nasopharyngeal carcinoma (NPC) is a malignancy where the role of CYP2E1 in nitrosamine-induced carcinogenesis is not fully understood.

Purpose of the Study:

  • To investigate the expression of CYP2E1 in NPC tissues and cell lines.
  • To establish and characterize a novel cell line for studying CYP2E1's metabolic activation of nitrosamines.

Main Methods:

  • RT-PCR analysis was used to detect CYP2E1 expression in NPC cell lines, embryonic nasopharyngeal epithelial tissue (ENET), and NPC biopsies.
  • A tetracycline-inducible cell line (NIH 3T3/rtTA) was engineered to stably express CYP2E1.
  • CYP2E1 catalytic activity was assessed by chlorzoxazone (CZ) 6-hydroxylase assay.
  • Cytotoxicity assays using N,N'-dinitrosopiperazine (DNP) were performed on the engineered cell line.

Main Results:

  • CYP2E1 was expressed in all tested NPC cell lines and ENET specimens, and in 80% of NPC biopsies.
  • The engineered cell line demonstrated dose- and time-dependent CYP2E1 activity regulated by Doxycycline (Dox).
  • The engineered cells showed increased sensitivity to DNP-induced cytotoxicity when CYP2E1 was induced, indicating metabolic activation.

Conclusions:

  • Human nasopharynx expresses CYP2E1, suggesting its potential role in NPC development through nitrosamine activation.
  • The developed cell line provides a valuable in vitro model for investigating CYP2E1's metabolic activation of carcinogenic nitrosamines.

More Related Videos

Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke09:50

Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke

Published on: February 12, 2015

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Drug Metabolism: Phase I Reactions01:17

Drug Metabolism: Phase I Reactions

A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...